Ask AI

Complement Inhibition in Generalized Myasthenia Gravis: Rationale, Mechanism of Action, and Clinical Trial Data

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: September 10, 2026

Expiration: September 09, 2027

See Activity Collection

Acetylcholine receptor antibodies are present in approximately 85% of patients with generalized myasthenia gravis, making complement-mediated injury an important therapeutic target for many patients. This expert commentary examines the biological rationale for complement inhibition, reviews pivotal evidence for approved C5 inhibitors and emerging complement-directed therapies, and explores how differences in mechanism, administration, efficacy, and safety are shaping the evolving treatment landscape.

Complement Inhibition Rationale Commentary

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with gMG do you provide care for in a typical month?​

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You are considering treatment with a complement inhibitor for your patient with AChR-positive gMG. She prefers a subcutaneous treatment she can self-administer rather than an infusion therapy. Which of these would you suggest?